253 related articles for article (PubMed ID: 15724236)
1. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
[TBL] [Abstract][Full Text] [Related]
2. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
3. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus.
Annuzzi G; De Natale C; Iovine C; Patti L; Di Marino L; Coppola S; Del Prato S; Riccardi G; Rivellese AA
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2397-402. PubMed ID: 15458975
[TBL] [Abstract][Full Text] [Related]
5. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance.
Annuzzi G; Giacco R; Patti L; Di Marino L; De Natale C; Costabile G; Marra M; Santangelo C; Masella R; Rivellese AA
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):531-8. PubMed ID: 18321693
[TBL] [Abstract][Full Text] [Related]
6. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
7. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
8. Is postprandial hypertriglyceridaemia in relatives of type 2 diabetic subjects a consequence of insulin resistance?
Kriketos A; Milner KL; Denyer G; Campbell L
Eur J Clin Invest; 2005 Feb; 35(2):117-25. PubMed ID: 15667583
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
12. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes.
Morita Y; Ueno T; Sasaki N; Tateishi Y; Nagata E; Kage M; Sata M
Hepatogastroenterology; 2005; 52(65):1338-43. PubMed ID: 16201069
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
[TBL] [Abstract][Full Text] [Related]
14. Postprandial lipaemia in patients with impaired fasting glucose, impaired glucose tolerance and diabetes mellitus.
Madhu SV; Kant S; Srivastava S; Kant R; Sharma SB; Bhadoria DP
Diabetes Res Clin Pract; 2008 Jun; 80(3):380-5. PubMed ID: 18321605
[TBL] [Abstract][Full Text] [Related]
15. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
16. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
Schmoelzer I; de Campo A; Pressl H; Stelzl H; Dittrich P; Oettl K; Wascher TC
Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
[TBL] [Abstract][Full Text] [Related]
17. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
Gallagher A; Home PD
Diabetes Res Clin Pract; 2005 Mar; 67(3):196-203. PubMed ID: 15713351
[TBL] [Abstract][Full Text] [Related]
18. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
Fu ZF; Liu ML
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):260-2. PubMed ID: 19552844
[TBL] [Abstract][Full Text] [Related]
19. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus.
da Silva RC; Miranda WL; Chacra AR; Dib SA
J Diabetes Complications; 2007; 21(2):84-92. PubMed ID: 17331856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
